Scholarlink

Objective <p>To investigate the expression of long non-coding RNA (lncRNA) apolipoprotein A-1 antisense RNA (APOA1-AS) in the serum of atherosclerosis (AS) patients and AS cell models, and its effects on cell proliferation, apoptosis, and underlying mechanisms.</p> Methods <p>Twenty angiography-confirmed coronary atherosclerosis patients (≥ 50% stenosis, never treated) were enrolled, excluding comorbidities (hypertension, diabetes, organ dysfunction, or tumors). Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect APOA1-AS and microRNA-185 (miR-185) in the serum of AS patients and healthy controls. AS cell models were created by treating human smooth muscle cells (HASMCs) with 100&#xa0;mg/L oxidized low-density lipoprotein (ox-LDL) for 24&#xa0;h. Cells were transfected with APOA1-AS small interfering RNA (si-APOA1-AS), miR-185 mimics, and si-APOA1-AS, followed by ox-LDL treatment. Cell proliferation was analyzed with Cell Counting Kit-8 (CCK8), and apoptosis with flow cytometry and Western blot. The interaction between APOA1-AS and miR-185 was confirmed by luciferase reporter assay.</p> Results <p>APOA1-AS and miR-185 levels were significantly higher in AS patients than in controls (P &lt; 0.001). In ox-LDL-treated HASMCs, APOA1-AS and miR-185 expression increased (P &lt; 0.001). APOA1-AS knockdown or miR-185 overexpression reduced proliferation and apoptosis, lowered Caspase3 and Bax, and elevated Bcl-2 (P &lt; 0.001). APOA1-AS intervenes in the expression of miR-185 (P &lt; 0.001) and directly binds miR-185 as a molecular sponge.</p> Conclusion <p>This study identifies APOA1-AS as a novel AS biomarker and demonstrates its pathogenic role in vascular smooth muscle cells (VSMC) dysfunction via miR-185 sponging. The APOA1-AS/miR-185 axis links lipid metabolism to VSMC remodeling, offering a dual-target strategy for plaque stabilization.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Apolipoprotein A-1 Antisense RNA Exacerbates Atherosclerosis by Targeting MicroRNA-185

  • 期刊论文

  • 发表日期：

    2025年5月26日

查看全文
  • Che Li,
  • Shanyong Wu,
  • Bin Zhang,
  • Jifeng Zheng,
  • Shenggang Zhao,
  • Jianqin Zhang,
  • Jianjiang Xu,
  • Zhenliang Chu

摘要

Objective

To investigate the expression of long non-coding RNA (lncRNA) apolipoprotein A-1 antisense RNA (APOA1-AS) in the serum of atherosclerosis (AS) patients and AS cell models, and its effects on cell proliferation, apoptosis, and underlying mechanisms.

Methods

Twenty angiography-confirmed coronary atherosclerosis patients (≥ 50% stenosis, never treated) were enrolled, excluding comorbidities (hypertension, diabetes, organ dysfunction, or tumors). Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect APOA1-AS and microRNA-185 (miR-185) in the serum of AS patients and healthy controls. AS cell models were created by treating human smooth muscle cells (HASMCs) with 100 mg/L oxidized low-density lipoprotein (ox-LDL) for 24 h. Cells were transfected with APOA1-AS small interfering RNA (si-APOA1-AS), miR-185 mimics, and si-APOA1-AS, followed by ox-LDL treatment. Cell proliferation was analyzed with Cell Counting Kit-8 (CCK8), and apoptosis with flow cytometry and Western blot. The interaction between APOA1-AS and miR-185 was confirmed by luciferase reporter assay.

Results

APOA1-AS and miR-185 levels were significantly higher in AS patients than in controls (P < 0.001). In ox-LDL-treated HASMCs, APOA1-AS and miR-185 expression increased (P < 0.001). APOA1-AS knockdown or miR-185 overexpression reduced proliferation and apoptosis, lowered Caspase3 and Bax, and elevated Bcl-2 (P < 0.001). APOA1-AS intervenes in the expression of miR-185 (P < 0.001) and directly binds miR-185 as a molecular sponge.

Conclusion

This study identifies APOA1-AS as a novel AS biomarker and demonstrates its pathogenic role in vascular smooth muscle cells (VSMC) dysfunction via miR-185 sponging. The APOA1-AS/miR-185 axis links lipid metabolism to VSMC remodeling, offering a dual-target strategy for plaque stabilization.